• Mark Lambrechts, Michael J O'Brien, Felix H Savoie, and Zongbing You.
• Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA ; Department of Orthopaedic Surgery and Tulane institute of Sports Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
• Patient Prefer Adher. 2013 Jan 1;7:885-90.

AbstractWhen physicians consider which analgesia to use postsurgery, the primary goal is to relieve pain with minimal adverse side effects. Bupivacaine, a commonly used analgesic, has been formulated into an aqueous suspension of multivesicular liposomes that provide long-lasting analgesia for up to 72 hours, while avoiding the adverse side effects of opioids. The increased efficacy of liposomal extended-release bupivacaine, compared to bupivacaine hydrochloride, has promoted its usage in a variety of surgeries including hemorrhoidectomy, bunionectomy, inguinal hernia repair, total knee arthroplasty, and augmentation mammoplasty. However, like other bupivacaine formulations, the liposomal extended-release bupivacaine does have some side effects. In this brief review, we provide an update of the current knowledge in the use of bupivacaine for postsurgical analgesia.

6 keywords...

hide…